Related references
Note: Only part of the references are listed.Independent Validation of a Prognostic Genomic Signature (ColoPrint) for Patients With Stage II Colon Cancer
Matthias Maak et al.
ANNALS OF SURGERY (2013)
T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer
Kathrin Bauer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Implementation of Universal Microsatellite Instability and Immunohistochemistry Screening for Diagnosing Lynch Syndrome in a Large Academic Medical Center
Brandie Heald et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prognostic value of innate and adaptive immunity in colorectal cancer
Fabio Grizzi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
H. J. Schmoll et al.
ANNALS OF ONCOLOGY (2012)
Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
Tomoya Yokota
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2012)
Use of Aspirin postdiagnosis improves survival for colon cancer patients
E. Bastiaannet et al.
BRITISH JOURNAL OF CANCER (2012)
Genome-wide differential genetic profiling characterizes colorectal cancers with genetic instability and specific routes to HLA class I loss and immune escape
Monica Bernal et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Impact of Preanalytic Factors on the Design and Application of Integral Biomarkers for Directing Patient Therapy
Stephen M. Hewitt et al.
CLINICAL CANCER RESEARCH (2012)
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
Xiaoyun Liao et al.
CLINICAL CANCER RESEARCH (2012)
Microsatellite Instability and Therapeutic Consequences in Colorectal Cancer
Luigi Laghi et al.
DIGESTIVE DISEASES (2012)
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
Carsten Bokemeyer et al.
EUROPEAN JOURNAL OF CANCER (2012)
Different mutation profiles associated to P53 accumulation in colorectal cancer
Ignacio Lopez et al.
GENE (2012)
FAM83B mediates EGFR- and RAS-driven oncogenic transformation
Rocky Cipriano et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Aspirin Use After Diagnosis Improves Survival in Older Adults with Colon Cancer: A Retrospective Cohort Study
Marlies S. Reimers et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2012)
Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials
Peter M. Rothwell et al.
LANCET (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
Xiaoyun Liao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
European cancer mortality predictions for the year 2011
M. Malvezzi et al.
ANNALS OF ONCOLOGY (2011)
Prediction of Prognosis Is Not Improved by the Seventh and Latest Edition of the TNM Classification for Colorectal Cancer in a Single-Center Collective
Ulrich Nitsche et al.
ANNALS OF SURGERY (2011)
Pharmacology and cellular/molecular mechanisms of action of aspirin and Non-aspirin NSAIDs in colorectal cancer
Karsten Schroer
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2011)
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
T. Yokota et al.
BRITISH JOURNAL OF CANCER (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Clinical Implications of UGT1A1*28 Genotype Testing in Colorectal Cancer Patients
Katerina Shulman et al.
CANCER (2011)
2011: the immune hallmarks of cancer
Federica Cavallo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Coxibs and Other Nonsteroidal Anti-Inflammatory Drugs in Animal Models of Cancer Chemoprevention
Susan M. Fischer et al.
CANCER PREVENTION RESEARCH (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer
Maarten J. Deenen et al.
CLINICAL CANCER RESEARCH (2011)
Prognostic and Predictive Markers in Stage II Colon Cancer: Is There a Role for Gene Expression Profiling?
Robin K. Kelley et al.
CLINICAL COLORECTAL CANCER (2011)
5-Fluorouracil Adjuvant Chemotherapy Does Not Increase Survival in Patients With CpG Island Methylator Phenotype Colorectal Cancer
Rodrigo Jover et al.
GASTROENTEROLOGY (2011)
Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer
Christine Nyiraneza et al.
HUMAN PATHOLOGY (2011)
Validation Study of a Quantitative Multigene Reverse Transcriptase-Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer
Richard G. Gray et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer
Ramon Salazar et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
Gordon Hutchins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer-A Study of CALGB 9581 and 89803
Monica M. Bertagnolli et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
KRAS and BRAF: drug targets and predictive biomarkers
Efsevia Vakiani et al.
JOURNAL OF PATHOLOGY (2011)
DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
Frank A. Sinicrope et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials
Peter M. Rothwell et al.
LANCET (2011)
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
John Burn et al.
LANCET (2011)
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
Wendy De Roock et al.
LANCET ONCOLOGY (2011)
Part 4: Pharmacogenetic Variability in Anticancer Pharmacodynamic Drug Effects
Maarten J. Deenen et al.
ONCOLOGIST (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Predictive and Prognostic Markers in Colorectal Cancer
Ben George et al.
CURRENT ONCOLOGY REPORTS (2011)
PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis
Arantza Farina Sarasqueta et al.
CELLULAR ONCOLOGY (2011)
Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin
A. Zaanan et al.
ANNALS OF ONCOLOGY (2010)
Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975
C. La Vecchia et al.
ANNALS OF ONCOLOGY (2010)
The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
A. Farina-Sarasqueta et al.
ANNALS OF ONCOLOGY (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Intratumoral CD8+ T/FOXP3+ cell ratio is a predictive marker for survival in patients with colorectal cancer
Hiroyuki Suzuki et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
The Predictive Value of HLA Class I Tumor Cell Expression and Presence of Intratumoral Tregs for Chemotherapy in Patients with Early Breast Cancer
Esther M. de Kruijf et al.
CLINICAL CANCER RESEARCH (2010)
Microsatellite instability as a marker of prognosis and response to therapy: A meta-analysis of colorectal cancer survival data
Cecilia Guastadisegni et al.
EUROPEAN JOURNAL OF CANCER (2010)
Estimates of cancer incidence and mortality in Europe in 2008
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2010)
The Chromosomal Instability Pathway in Colon Cancer
Maria S. Pino et al.
GASTROENTEROLOGY (2010)
Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity
Andre B. P. van Kuilenburg et al.
HUMAN GENETICS (2010)
Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer
Shahab Uddin et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Phase III Randomized Trial Assessing Rofecoxib in the Adjuvant Setting of Colorectal Cancer: Final Results of the VICTOR Trial
Rachel S. Midgley et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Relationship Between Tumor Gene Expression and Recurrence in Four Independent Studies of Patients With Stage II/III Colon Cancer Treated With Surgery Alone or Surgery Plus Adjuvant Fluorouracil Plus Leucovorin
Michael J. O'Connell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Daniel J. Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Arnaud D. Roth et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
HLA-E and HLA-G Expression in Classical HLA Class I-Negative Tumors Is of Prognostic Value for Clinical Outcome of Early Breast Cancer Patients
Esther M. de Kruijf et al.
JOURNAL OF IMMUNOLOGY (2010)
Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review
Katsuhiko Nosho et al.
JOURNAL OF PATHOLOGY (2010)
Oncogenic mutations as predictive factors in colorectal cancer
A. Lievre et al.
ONCOGENE (2010)
PI3-kinase/Wnt association mediates COX-2/PGE2 pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac
Jasmeet Kaur et al.
TUMOR BIOLOGY (2010)
Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer
M. Gusella et al.
BRITISH JOURNAL OF CANCER (2009)
Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis
O. Fluge et al.
BRITISH JOURNAL OF CANCER (2009)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients
Youji He et al.
CLINICAL CANCER RESEARCH (2009)
Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review
Glenn E. Palomaki et al.
GENETICS IN MEDICINE (2009)
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
Shuji Ogino et al.
GUT (2009)
Aspirin Use and Survival After Diagnosis of Colorectal Cancer
Andrew T. Chan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Prognostic Significance and Molecular Associations of 18q Loss of Heterozygosity: A Cohort Study of Microsatellite Stable Colorectal Cancers
Shuji Ogino et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803
Monica M. Bertagnolli et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan
Erika Cecchin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
PIK3CA Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
Shuji Ogino et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer
Paul Salama et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Aspirin, salicylates, and cancer
Peter C. Elwood et al.
LANCET (2009)
Molecular Origins of Cancer: Molecular Basis of Colorectal Cancer.
Sanford D. Markowitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Genetic prognostic and predictive markers in colorectal cancer
Axel Walther et al.
NATURE REVIEWS CANCER (2009)
The staging of cancer: A retrospective and prospective appraisal
Frederick L. Greene et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
The clinical significance of lymph node micrometastasis in stage I and stage II colorectal cancer
Mark Davies et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2008)
Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy
Bret B. Friday et al.
CLINICAL CANCER RESEARCH (2008)
Variability and Function of Family 1 Uridine-5′-Diphosphate Glucuronosyltransferases (UGT1A)
Christian P. Strassburg et al.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2008)
Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis
A. Walther et al.
GUT (2008)
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers
Ludovic Barault et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer
Yuqiu Jiang et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2008)
The impact of T and N stage on long-term survival of rectal cancer patients in the community
Kevin R. Kozak et al.
JOURNAL OF SURGICAL ONCOLOGY (2008)
Differences and evolution of the methods for the assessment of microsatellite instability
L. Laghi et al.
ONCOGENE (2008)
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
W. De Roock et al.
ANNALS OF ONCOLOGY (2008)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Caspase-3 activity predicts local recurrence in rectal cancer
Pieter de Heer et al.
CLINICAL CANCER RESEARCH (2007)
Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer
Ken-Ichi Fujita et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese:: roles of UGT1A1*6 and*28
Hironobu Minami et al.
PHARMACOGENETICS AND GENOMICS (2007)
AKT/PKB signaling: Navigating downstream
Brendan D. Manning et al.
CELL (2007)
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use
M. J. Duffy et al.
EUROPEAN JOURNAL OF CANCER (2007)
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2
Andrew T. Chan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
F. Di Fiore et al.
BRITISH JOURNAL OF CANCER (2007)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
Silvia Benvenuti et al.
CANCER RESEARCH (2007)
Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study
George P. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer
Yu-Hsin Lin et al.
CLINICAL CANCER RESEARCH (2007)
Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity
Tessa M. Bosch et al.
MOLECULAR DIAGNOSIS & THERAPY (2007)
HLA-A, -B, -C expression in colon carcinoma mimics that of the normal colonic mucosa and is prognostically relevant
Maria Benevolo et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
Hyperactive Ras in developmental disorders and cancer
Suzanne Schubbert et al.
NATURE REVIEWS CANCER (2007)
Tumor infiltrating FOXP3+ regulatory T-cells are associated with recurrence in pathologic stage INSCLC patients
Rebecca P. Petersen et al.
CANCER (2006)
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse
Gaynor J. Bates et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
Gershon Y. Locker et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic value of apoptosis in rectal cancer patients of the Dutch Total Mesorectal Excision trial: Radiotherapy is redundant in intrinsically high-apoptotic tumors
Elza C. de Bruin et al.
CLINICAL CANCER RESEARCH (2006)
Stage II colon cancer prognosis prediction by tumor gene expression profiling
Alain Barrier et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Cancer despite immunosurveillance: immunoselection and immunosubversion
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2006)
More extensive nodal dissection improves survival for stages I to III of colon cancer - A population-based study
Steven L. Chen et al.
ANNALS OF SURGERY (2006)
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians
Lori Kay Mattison et al.
CLINICAL CANCER RESEARCH (2006)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
The role of UGT1A1*28 polymorphism in the pharmacodynarnics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
Giuseppe Toffoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A prospective analysis of microsatellite instability as a molecular marker in colorectal cancer
Eugene Y. Chang et al.
AMERICAN JOURNAL OF SURGERY (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis
NFS Watson et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan
Swati Nagar et al.
DRUG METABOLISM REVIEWS (2006)
Microsatellite instability and colorectal cancer prognosis
P Benatti et al.
CLINICAL CANCER RESEARCH (2005)
Total loss of MHC class I is an independent indicator of good prognosis in breast cancer
Z Madjd et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma
A Conlin et al.
GUT (2005)
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers
WS Samowitz et al.
CANCER RESEARCH (2005)
BAD detects coincidence of G2/M phase and growth factor deprivation to regulate apoptosis
A Hashimoto et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer
Eeva Salminen et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas:: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study
V. Bazan et al.
ANNALS OF ONCOLOGY (2005)
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
M Moroni et al.
LANCET ONCOLOGY (2005)
Low microsatellite instability is associated with poor prognosis in stage C colon cancer
MRJ Kohonen-Corish et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
KY Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Opinion - The role of apoptosis in cancer development and treatment response
JM Brown et al.
NATURE REVIEWS CANCER (2005)
Systematic review of microsatellite instability and colorectal cancer prognosis
S Popat et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected dukes' B2 or C colon cancer: A North Central Cancer Treatment Group study
MM Garrity et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
F Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
LB Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis
AG Menon et al.
LABORATORY INVESTIGATION (2004)
Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas
K Fransén et al.
CARCINOGENESIS (2004)
Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer
Y Parc et al.
GUT (2004)
Simultaneous mutations in K-ras and TP53 are indicative of poor prognosis in sporadic colorectal cancer
JJ González-Aguilera et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2004)
American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer
AB Benson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group trial 92-02
A Pollack et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Colon cancer survival rates with the new American Joint Committee on cancer sixth edition staging
JB O'Connell et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Prognostic value of carbonic anhydrase IX and Ki67 as predictors of survival for renal clear cell carcinoma
MHT Bui et al.
JOURNAL OF UROLOGY (2004)
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer:: Who benefits and by how much?
S Gill et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: A pooled analysis
LL Gunderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Mechanisms of disease: Gene silencing in cancer in association with promoter hypermethylation
JG Herman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Potential role of bcl-2 and Ki-67 expression and apoptosis in colorectal carcinoma - A clinicopathologic study
CD Scopa et al.
DIGESTIVE DISEASES AND SCIENCES (2003)
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
CM Ribic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines
MJ Duffy et al.
EUROPEAN JOURNAL OF CANCER (2003)
Molecular prognostics in colorectal cancer
MS Kahlenberg et al.
SURGICAL ONCOLOGY-OXFORD (2003)
Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients
AG Menon et al.
LABORATORY INVESTIGATION (2002)
DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study
PL Barratt et al.
LANCET (2002)
Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)
JF Gagné et al.
MOLECULAR PHARMACOLOGY (2002)
Tumorigenesis -: RAF/RAS oncogenes and mismatch-repair status
H Rajagopalan et al.
NATURE (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability
N Hawkins et al.
GASTROENTEROLOGY (2002)
The treatment of advanced colorectal cancer: where are we now and where do we go?
E Van Cutsem et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2002)
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
HJN Andreyev et al.
BRITISH JOURNAL OF CANCER (2001)
Caspase-3 activity as a prognostic factor in colorectal carcinoma
LE Jonges et al.
LABORATORY INVESTIGATION (2001)
Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
T Watanabe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601
BH Zhang et al.
EMBO JOURNAL (2000)
Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy
A Hemminki et al.
GASTROENTEROLOGY (2000)
Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer
H Elsaleh et al.
LANCET (2000)
Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer
R Gryfe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Apoptosis in rectal cancer - Prognostic significance in comparison with clinical, histopathologic, and immunohistochemical variables
O Schwandner et al.
DISEASES OF THE COLON & RECTUM (2000)
Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and pRb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy
R Kirla et al.
JOURNAL OF NEURO-ONCOLOGY (2000)
Share Paper
